Neurosense Therapeutics is trading at $2.63, up +12.39%, alongside biotech-sector strength, though no direct company-specific catalyst was confirmed for the October 21 move.
- The latest company announcement was an October 19 PrimeC patent application for traumatic brain injury; the filing predates the move.
- Reports cited merger activity and clinical-trial news as support for a broader biotech-sector rally.